Litigation Details for IN RE: Ozempic (Semaglutide) Patent Litigation (J.P.M.L. 2022)
✉ Email this page to a colleague
IN RE: Ozempic (Semaglutide) Patent Litigation (J.P.M.L. 2022)
Docket | ⤷ Try a Trial | Date Filed | 2022-05-06 |
Court | United States Judicial Panel on Multidistrict Litigation | Date Terminated | |
Cause | Assigned To | Colm F. Connolly | |
Jury Demand | Referred To | ||
Patents | 10,220,155; 10,335,462; 10,357,616; 10,376,652; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in IN RE: Ozempic (Semaglutide) Patent Litigation
Biologic Drugs cited in IN RE: Ozempic (Semaglutide) Patent Litigation
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for IN RE: Ozempic (Semaglutide) Patent Litigation (J.P.M.L. 2022)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2022-08-05 | 29 | ; 9,616,180; 9,687,611; 9,775,953; 9,861,757; 10,220,155; 10,335,462; 10,357,616; 10,376,652; and 11,097,063… infringed two or more of the Ozempic patents. While the patents asserted in each action vary somewhat…Valsartan) Patent Litig., 437 F. Supp. 3d 1372, 1373 (J.P.M.L. 2020); In re Palbociclib Patent Litig., 396…unique patents, this may be a temporary distinction. Further, many of the “non-common” patents asserted…West Virginia action derive from the same patent family as patents asserted in the Delaware actions, and | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |